uniQure (QURE) – Company Press Releases
-
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
-
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
-
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People L
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
-
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
CSL and uniQure Win 2023 Prix Galien USA Award
-
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
-
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
-
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
-
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
-
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
-
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
-
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure to Participate in Multiple Upcoming Industry Conferences in March
-
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
-
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
-
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
-
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
-
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
-
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
-
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treat
-
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
-
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
-
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
-
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
-
VectorY Appoints Sander van Deventer as CEO and Makes Key Appointments to Its Leadership Team
-
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
-
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
-
uniQure to Participate in Upcoming Industry Conferences in October
-
uniQure to Participate in Upcoming Industry Conferences in September
-
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
-
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
-
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
-
FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
Back to QURE Stock Lookup
